Blue Horseshoe Stocks: Fresh Options Ideas & More

Pazoo Inc. PZOO

PZOO has been progressing well in the past several sessions since we last touched base with the stock a couple of weeks ago. We had just received word from the company that its wholly-owned CannabisKing Distribution subsidiary had struck two significant deals (Links to PR’s below), and witnessed a two-session swing of 74% as a result.

After regrouping and bouncing off of a low of .0046 (07/13), PZOO has made continuously higher lows for the rest of this month, and pushed its PPS back to the current range (.006-.007). We’ve provided the following snapshot illustrating the current bullish characteristics of the chart.

We’ll be on the lookout for further updates regarding the many irons PZOO currently has in the fire, and you can be sure that we’ll pass them along as the stories develop.


Fresh Options Ideas

As we approach midweek with earnings drops in full swing, we’re going to formulate a few corresponding options ideas we feel have the potential to perform well:

Ford Motor Co. (F) – Ford set record North American profits and beat Wall St. expectations handily this morning. The stock is gapping up moderately, so we’re going to taking a look at F Weekly $14.50 and $15 Calls, which should produce some nice action.

Pfizer, Inc. PFE –  Pfizer also had an earnings beat on their Q2 release today, and our related options ideas will be to monitor PFE Weekly $34.50 and $35 Calls.

Baidu, Inc. BIDU – After an extreme analyst downgrade, BIDU is taking an absolute beating, and is leading us to include a rare idea on the bearish side of things; we’ll be tracking BIDU Weekly Puts in the $180-175 Range.


Cytori Therapeutics, Inc. CYTX

We also want to raise a flag on a familiar stock cropping up in the news feed this morning. Early this year we saw CYTX make a huge move, and after spending the last several months in a general downtrend, some FDA-related news out this morning could be just the thing to catalyze a reversal. We’ll be watching intently for that possibility; check out the news below.

Cytori Therapeutics, Inc. (CYTX) today announced that Kerastem Technologies, a wholly owned subsidiary of Bimini Technologies, received U.S. Food and Drug Administration (FDA) conditional Investigational Device Exemption (IDE) approval to conduct a clinical trial studying the safety and feasibility of its technology for the treatment of female and early male pattern baldness (androgenic alopecia). >> FULL PR


Extended Watchlist:
PGNX, SDRL, NYMX, AKS, RJET